T. Rowe Price Associates
STRO icon

T. Rowe Price Associates’s Sutro Biopharma STRO Stock Holding History

T. Rowe Price Associates’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,689
Closed -$25K – 3144
2025
Q1 		$25K Buy
3,689
+669
+22% +$10.5K ﹤0.01% 2995
2024
Q4 		$56K Buy
3,020
+394
+15% +$12K ﹤0.01% 2924
2024
Q3 		$91K Hold
2,626
– – ﹤0.01% 2837
2024
Q2 		$77K Buy
2,626
+823
+46% +$32.5K ﹤0.01% 2788
2024
Q1 		$102K Buy
1,803
+358
+25% +$15.8K ﹤0.01% 2781
2023
Q4 		$62K Buy
1,445
+134
+10% +$4.25K ﹤0.01% 2777
2023
Q3 		$46K Buy
1,311
+156
+14% +$6.8K ﹤0.01% 2788
2023
Q2 		$54K Buy
+1,155
New +$57.5K ﹤0.01% 2793
2021
Q2 		– Sell
-2,140
Closed -$487K – 2952
2021
Q1 		$487K Buy
2,140
+43
+2% +$10.2K ﹤0.01% 2383
2020
Q4 		$455K Buy
+2,097
New +$347K ﹤0.01% 2281

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

T. Rowe Price Associates's STRO Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 3,689 shares — an estimated $25K sold.

T. Rowe Price Associates first reported a position in STRO in Q4 2020 and held it in 10 quarters. The position peaked at $487K in Q1 2021. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,689 Sutro Biopharma shares in Q2 2025, an estimated $25K.
  • T. Rowe Price Associates first reported a position in Sutro Biopharma in Q4 2020 and held it in 10 quarters.
  • T. Rowe Price Associates's Sutro Biopharma position peaked at $487K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.